search
Back to results

Safety and Efficacy of a Novel Hydrophobic Acrylic IOL - iPure: a Randomised Study

Primary Purpose

Cataract

Status
Completed
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
Cataract surgery
Sponsored by
Vienna Institute for Research in Ocular Surgery
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cataract

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age-related cataract
  • Age 21 and older
  • Visual Acuity > 0.05
  • Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant.

Exclusion Criteria:

  • Relevant other ophthalmic diseases such as pseudoexfoliation syndrome, floppy iris syndrome, corneal pathologies
  • Previous ocular surgery or trauma.
  • Pregnancy (pregnancy test will be taken pre-operatively in women of reproductive age)

Sites / Locations

  • Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

iPure

ZCB00

Arm Description

A new single-piece hydrophobic acrylic IOL (IPure IOL). The study IOL is a one-piece aspheric acrylic hydrophobic glistening-free lens, with a 4.9% water content, a 360 square posterior edge design, and a 5 haptic angulation, providing UV and blue-light filtration. Patient were allocated into two groups. The study group received the iPure lens while the control group received Tecnis ZCB00. Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation.

A standard IOL (ZCB00).The control IOL, is a one-piece hydrophobic acrylic IOL with a biconvex aspheric optic and 360 continuous square posterior optic edge with a UV filter and an offset, stepped haptic design. Patient were allocated into two groups. The study group received the iPure lens while the control group received Tecnis ZCB00. Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation.

Outcomes

Primary Outcome Measures

Rotational Stability
measured using the Purkinje meter (Murcia University) and retroillumination images (degrees of rotation)

Secondary Outcome Measures

Glistening
subjective measurement (0 to 4, 0 no glistening, 4 sever glistening)
visual acuity
assessed by ETDRS charts at 4m
PCO
scored with AQUA (0 to 10, 0 no PCO, 10 sever PCO) and the number of Nd:YAG capsulotomies
Decentration in mm
measured by Purkinjemeter
Tilt in degrees
measured by Purkinjemeter
Capsulorhexis area
assessed by retroillumination images
Anterior chamber depth
assessed by AC Master (in mm)

Full Information

First Posted
January 25, 2013
Last Updated
October 12, 2022
Sponsor
Vienna Institute for Research in Ocular Surgery
search

1. Study Identification

Unique Protocol Identification Number
NCT04329754
Brief Title
Safety and Efficacy of a Novel Hydrophobic Acrylic IOL - iPure: a Randomised Study
Official Title
Safety and Efficacy of a Novel Hydrophobic Acrylic IOL - iPure: a Randomised Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
April 2012 (undefined)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
February 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vienna Institute for Research in Ocular Surgery

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In this study the rotational stability and performance - with respect to glistening and PCO formation - of a new hydrophobic acrylic IOL (IPure, PhysIOL, Belgium) will be compared to a gold standard IOL (AMO ZCB00) in a randomized controlled fashion. Fifty eyes of 50 patients will be included. 25 patients will receive the iPure and 25 patients will receive the standard IOL. Study hypothesis: The iPure IOL shows better rotational stability compared to the standard IOL. A clinically relevant difference for rotational stability is defined as 2°.
Detailed Description
Although there may be no direct benefit to the subjects under study, the investigation will assess the stability which determines the efficacy for future toric optics and the amount of glistening and PCO formation of the IPure and ZCB00 hydrophobic acrylic IOLs. 25 eyes of 25 patients will be recruited for each IOL, that is 50 eyes of 50 patients. The randomization will be done with a binomial law. The IOL have a priori the same IOL constants which eliminates the necessity to know which IOL is going to be implanted at the preoperative time. A clinically relevant difference for rotational stability will be 2°. The reasonable standard deviation of the position of an IOL in the eye is 2.4°. A total of 48 patients is necessary for a probability of 80% to measure a clinically relevant difference concerning the IOL stability. In the week before surgery, the eye to be operated is examined at the slit-lamp and by indirect fundoscopy and measurement of intraocular pressure (IOP) will be performed routinely. Additionally, routine biometry is performed using the IOLMaster (Zeiss Meditec AG, Jena, Germany) for axial length measurement, K-readings and anterior chamber depth (ACD) measurements. Randomisation will be performed using online randomisation and patients will be allocated 1:1 either to the study group (iPure group), or to the control group (ZCB00). A self sealing incision, injection of viscoelastic substance, capsulorhexis, phacoemulsification, irrigation/aspiration of cortical material and injection of viscoelastic substance into the capsular bag are performed in a standardised fashion. The IOL is implanted via injector into the capsular bag. Following the implantation of the IOL, the viscoelastic substance is aspirated thoroughly from the anterior chamber, as well as retro-lentally, to assure complete removal of the OVD. Any deviation from the standard protocol will be recorded peroperatively. Follow-ups will be performed 1-2 hours, 1 month, 12 months and 24 months after cataract surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cataract

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
55 (Actual)

8. Arms, Groups, and Interventions

Arm Title
iPure
Arm Type
Other
Arm Description
A new single-piece hydrophobic acrylic IOL (IPure IOL). The study IOL is a one-piece aspheric acrylic hydrophobic glistening-free lens, with a 4.9% water content, a 360 square posterior edge design, and a 5 haptic angulation, providing UV and blue-light filtration. Patient were allocated into two groups. The study group received the iPure lens while the control group received Tecnis ZCB00. Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation.
Arm Title
ZCB00
Arm Type
Other
Arm Description
A standard IOL (ZCB00).The control IOL, is a one-piece hydrophobic acrylic IOL with a biconvex aspheric optic and 360 continuous square posterior optic edge with a UV filter and an offset, stepped haptic design. Patient were allocated into two groups. The study group received the iPure lens while the control group received Tecnis ZCB00. Randomisation was done with a binomial law, using random.org. The surgeon was masked to IOL allocation until shortly before implantation. Examiners were masked to IOL allocation.
Intervention Type
Device
Intervention Name(s)
Cataract surgery
Intervention Description
Cataract surgery with implantation of an intraocular lens (IOL)
Primary Outcome Measure Information:
Title
Rotational Stability
Description
measured using the Purkinje meter (Murcia University) and retroillumination images (degrees of rotation)
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Glistening
Description
subjective measurement (0 to 4, 0 no glistening, 4 sever glistening)
Time Frame
2 years
Title
visual acuity
Description
assessed by ETDRS charts at 4m
Time Frame
2 years
Title
PCO
Description
scored with AQUA (0 to 10, 0 no PCO, 10 sever PCO) and the number of Nd:YAG capsulotomies
Time Frame
2 years
Title
Decentration in mm
Description
measured by Purkinjemeter
Time Frame
2 years
Title
Tilt in degrees
Description
measured by Purkinjemeter
Time Frame
2 years
Title
Capsulorhexis area
Description
assessed by retroillumination images
Time Frame
2 years
Title
Anterior chamber depth
Description
assessed by AC Master (in mm)
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age-related cataract Age 21 and older Visual Acuity > 0.05 Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant. Exclusion Criteria: Relevant other ophthalmic diseases such as pseudoexfoliation syndrome, floppy iris syndrome, corneal pathologies Previous ocular surgery or trauma. Pregnancy (pregnancy test will be taken pre-operatively in women of reproductive age)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Oliver Findl, MD, MBA
Organizational Affiliation
VIROS, Hanusch Hospital Vienna
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna
City
Vienna
ZIP/Postal Code
1140
Country
Austria

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy of a Novel Hydrophobic Acrylic IOL - iPure: a Randomised Study

We'll reach out to this number within 24 hrs